IMCS designs develops, manufactures, and distributes next-generation recombinant proteins and chromatography consumables to clinical and forensic toxicology, academic research facilities, US Federal Government agencies, and health science companies in North America, Europe, and Asia.  The company has two product lines: IMCSzyme® and IMCStips®. The industry-disrupting IMCSzyme is a genetically modified enzyme primarily used by clinical, forensic, and pain care laboratories for the drug screening and analysis of urine and other biological samples. IMCStips are advanced micro-chromatrography products centered around patented dispersive solid-phase extraction (dSPE) technology that contain loosely packed resin for faster biochemical purification processes. IMCStips are utilized by academic laboratories and health science companies for purifying new proteins, antibodies and enzymes, as part of drug target discovery and validation, drug development, drug screening, and drug manufacturing.  Recently, IMCS was awarded NIH SBIR funds to manufacture various glycosyltransferases to leverage its advanced manufacturing and research capabilities to expand synthesis of glycosphingolipids and sialoglycans. This expansion provides IMCS with new product lines and enables it to manufacture affordable, critically needed biological reagents that were not previously available to the scientific community.